OncoDNA Signs Agreement with SOLTI to Provide Tumor Molecular Profile Analysis to Breast Cancer Patients in AGATA Screening Program

AGATA Aims to Link Patients to Clinical Studies with Targeted Drugs
Based on their Individual Tumors

BRUSSELS & BARCELONA, Spain–(BUSINESS WIRE)–Belgium-based OncoDNA SA, The Cancer Theranostic Company, which supplies
the only comprehensive solution from cancer profiling (OncoDEEP&TRACE),
combining solid and liquid biopsies analysis to help oncologists with
drug treatment options and efficacy monitoring, has signed a partnership
agreement, through its Spanish distributor BioSequence, with SOLTI, a
non-profit organization dedicated to clinical research in breast cancer
with a broad network of leading hospital centers in Spain, Portugal,
France and Italy to supply tumor molecular profiling analysis for
SOLTI’s AGATA breast cancer screening program.

AGATA, the pilot trial of a genomic screening program pioneered in
Spain, aims to refer breast cancer patients to clinical trials based on
their molecular profile. With this partnership, SOLTI takes advantage of
OncoDNA’s solid experience in data processing to streamline and
customize patient data collection.

“This collaboration is a great opportunity to exchange knowledge and
know-how between OncoDNA and SOLTI, both organizations focused on
improving cancer patient care. We are excited to work together to
enhance the outcomes we provide through the AGATA program to better
direct patients to clinical trials according to their tumor profile,”
said Dr. Eva Ciruelos, President of SOLTI.

As part of the agreement, OncoDNA will customize its OncoKDM (Knowledge
Drive Medicine) platform to answer the specific needs of AGATA, allowing
the integration of three different types of DNA data (Illumina NGS, Ion
Torrent NGS and Sequenom Massarray), RNA expression profiling data and
proteomic data. Based on this integration, OncoKDM will generate a
theranostic report, which will quantify the OncoKDM platform’s
effectiveness assessment of AGATA.

OncoDNA’s aims to change and advance cancer care by bringing tomorrow’s
Cancer Precision Medicine to today’s oncologists’ daily practice. One of
the three axes to reach this goal is to provide academic research
groups, pathology labs, pharmaceutical and biotech companies with its
OncoKDM solution.

Jean-François Laes, CTO of OncoDNA, said: “We are happy that the first
OncoKDM collaboration we can announce publicly is with this renowned
SOLTI breast cancer group. Our goal when we developed OncoKDM was to
propose access to our database and share our expertise. This project
gathering molecular data from different technology and geographical
origins illustrates the advantage of a centralized, harmonized and
expert oncology system to improve cancer patient care.”

About OncoDNA SA

Based in Belgium, OncoDNA is an affiliated company of IPG (Institute of
Pathology and Genetics) and is a leading company specialized in the
personalized molecular analysis of cancer patients. OncoDNA currently
has three services, OncoDEEP&TRACE, OncoDEEP and OncoTRACE. These
medical innovations assist medical doctors with treatment choice and/or
provide better monitoring of tumor evolution in patients. For more
information, please visit www.oncodna.com.


SOLTI is a non-profit association with more than 20 years of experience
in conducting innovative clinical and translational research to address
unmet medical needs in breast cancer that answer questions of major
scientific interest and relevance in the field of oncology. SOLTI has a
network of more than 220 professionals, mostly medical oncologists,
distributed in over 60 hospitals in Spain, Portugal, France and Italy.
For more information, please visit: www.gruposolti.org.


Jonathan Lecocq
Communication and Social
Media Manager
Email: jonathan.lecocq@oncodna.com
Communication Manager
Telf. +34 93 343 63 02